Vetter becomes a member of the German Association of Research-Based Pharmaceutical Companies (vfa)

© Vetter Pharma International GmbH: Vetter is a strong partner for research-based pharma and biotech companies in the field of the development, manufacturing and packaging of complex injectable drugs.

- Association grants Vetter extraordinary membership  

- vfa recognizes the importance of pharmaceutical service providers in drug development and production  

- Vetter serves on key vfa committees 

Vetter, a leading globally operating contract development and manufacturing organization (CDMO), has joined the German Association of Research-Based Pharmaceutical Companies (vfa) as an associate member. With this membership, the vfa recognizes the significant role that the pharmaceutical service provider plays in the field of complex injectable drugs. Vetter supports research-based pharmaceutical companies worldwide in successfully developing, launching, and establishing their products on the market through the joint development of patient-friendly drug-delivery systems, innovative and flexible filling processes, and packaging solutions. Currently at 48 member companies, the vfa represents more than two thirds of the entire German pharmaceutical market. The companies employ around 94,000 people in Germany. More than 20,000 of them work in the research and development of medicinal products.